Health care products maker Abbott Laboratories (NYSE: ABT) received US Food and Drug Administration approval to market its new glucose monitoring system for the nearly 26 million US diabetics who take insulin. The company said the device would be available in the US “in the coming months.”
Shares are up 2.45% at $57.64, after posting a new 52-week high of $57.66 earlier.